Business News • PR NewsWire • Cell Therapeutics Acquires Exclusive Marketing and Co-Development Rights in the Americas to Chroma Therapeutics' Tosedostat, a First in Class Tumor Selective Oral Therapy for Treatment of Blood Related and Other Cancers

Cell Therapeutics Acquires Exclusive Marketing and Co-Development Rights in the Americas to Chroma Therapeutics' Tosedostat, a First in Class Tumor Selective Oral Therapy for Treatment of Blood Related and Other Cancers

Cell Therapeutics Acquires Exclusive Marketing and Co-Development Rights in the Americas to Chroma Therapeutics' Tosedostat, a First in Class Tumor Selective Oral Therapy for Treatment of Blood Related and Other Cancers

SEATTLE and OXFORD, England, March 14, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) and Chroma Therapeutics Ltd. ("Chroma") announced today that the companies have entered into a co-development and license agreement providing CTI with exclusive marketing and co-develop

View More : http://www.prnewswire.com/news-releases/cell-therapeutics-acquires-exclusive-marketing-and-co-development-rights-in-the-...

Releted News by prnewswire

Cryo Workstation Breaks World Records

HL Technology Group 2010 Net Profit Jumps 75.1% to RMB155.0 Million

R&D Productivity Measures Consistently Under-Scored and Under-Valued, EvaluatePharma Data Reveals

Apple or Google: Which Stock Will Perform Better?

Global Immune Technologies Executes Sales Agreement with French Distributor